Hydrocortisone Patent Expiration
Hydrocortisone is Used for treating adrenal insufficiency. It was first introduced by Merck And Co Inc
Hydrocortisone Patents
Given below is the list of patents protecting Hydrocortisone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Khindivi | US11904046 | Feb 23, 2043 | Eton | |
| Khindivi | US12133914 | Hydrocortisone Oral Liquid Formulations | Feb 23, 2043 | Eton |
| Alkindi Sprinkle | US9649280 | Composition comprising hydrocortisone | May 12, 2034 | Eton |
| Alkindi Sprinkle | US9675559 | Treatment of adrenal insufficiency | Jan 10, 2033 | Eton |
| Alkindi Sprinkle | US9717740 | Treatment of adrenal insufficiency | Nov 19, 2032 | Eton |
About Veterinary Hydrocortisone
Hydrocortisone has petitions filed by 1 petitioner: Akorn Animal Health Inc.
Hydrocortisone Petitions
Details of Hydrocortisone's suitability petitions are listed below.
| Petitioner | Action | Date of Action | Description |
|---|---|---|---|
 | |||
| Akorn Animal Health Inc. | Approved | ||
Hydrocortisone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Hydrocortisone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
